Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed · Phase 1

Conditions studied: Locally Advanced Non-small Cell Lung Cancer

In brief

The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.

Key facts

Study ID

NCT01059552

Run by

Fox Chase Cancer Center

People needed

18

Starts

2009-12-16

Expected to finish

2019-10-21

Last updated by the study team

2019-11-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• biopsy proven non-squamous NSCLC with unresectable stage IIIA or dry IIIB disease.
• FEV1 >/= 1 liter
• ECOG PS 0 or 1
• Able to swallow and absorb enterally
• Measurable disease per RECIST 1.1
• Adequate organ and marrow function including calculated creatinine clearance >/= 60 mL/min hepatic enzymes and alk phos </= 2.5 X ULN.

You may not qualify if…

• Chemotherapy or radiotherapy </= 4 weeks prior to registration (6 weeks for nitrosureas)
• Active bleeding
• Known brain mets
• Prior thoracic radiotherapy that would lead to overlap with current radiation field.
• More than 10% weight loss in 6 months.
• Pancoast tumors, supraclavicular or contralateral hilar lymph node involvement
• Known HIV positive
• Prior treatment with an HDAC inhibitor

Where it is running

• Moffitt Cancer Center — Tampa, Florida, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.